M&A drama: Endo takes on a spoiler role in the Valeant bid for Salix

Endo International Plc; Market Cap (as of 13/03/2015): $15.4bn Salix Pharmaceuticals Ltd; Market Cap (as of 13/03/2015): $10.8bn Valeant Pharmaceuticals Intl, Inc.; Market Cap (as of 13/03/2015): $63.9bn The pharmaceutical sector has turned into a war-zone again with of the bidding war between two aggressive dealmakers and two ex-colleagues: Mr. Read more…

Valeant, the serial pharma dealmaker cuts again

Valeant Pharmaceuticals International, Inc.; market cap (as of 26/02/2015): US$76.68bn Salix Pharmaceuticals, Ltd.; market cap (as of 26/02/2015): US$10.07bn     Introduction The pharmaceutical industry has undergone an intense period of consolidation in the past 18 months which is far from over as the big players take advantage of the Read more…

Get a $66bn Smile: Actavis to buy the Botox-maker Allergan

Actavis plc.; market cap (as of 21/11/2014): $70.5bn Allergan Inc.; market cap (as of 21/11/2014): $63.3bn Introduction The growing emphasis we put on health and quality of life, and the scientific advancements which are making this possible, are putting the pharmaceutical and medical industries in the spotlight. The recent surge Read more…

Scramble to fend off takeover: Allergan vs. Valeant

Valeant Pharmaceuticals International; Market Cap. (as of 3/10/2014): $42.9bn Allergan Inc.; Market Cap. (as of 3/10/2014): $53.64bn As low debt obligations alongside large cash holdings and patent expiration liabilities continue to foster a conducive environment for M&A activity in the pharmaceutical and biotech industry another multi-billion dollar struggle has emerged: Read more…